Desuden gælder, at under indikationen koronar hjertesygdom er indikationen “ reduktion af progression af koronararteriesklerose og reduktion af kardiale hændelser ” kun i nogle medlemsstater godkendt som særskilte indikationer.
Furthermore, within the Coronary Heart Disease indication “ slowing of the progression of coronary artery sclerosis and reduction of the incidence of cardiac events” were approved as separate indications only in some Member States.